Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 2
2011 2
2012 1
2013 8
2014 7
2015 5
2016 13
2017 10
2018 8
2019 9
2020 6
2021 10
2022 5
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
Domański P, Piętak M, Staneta S, Fortuniak W, Kruczyk B, Kobiernik A, Bakuła P, Mydlak A, Demkow T, Sikora-Kupis B, Dumnicka P, Kucharz J. Domański P, et al. Among authors: dumnicka p. Medicina (Kaunas). 2024 Feb 26;60(3):398. doi: 10.3390/medicina60030398. Medicina (Kaunas). 2024. PMID: 38541124 Free PMC article. Review.
Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study.
Domański P, Piętak M, Kruczyk B, Jarosińska J, Mydlak A, Demkow T, Darewicz M, Sikora-Kupis B, Dumnicka P, Kamzol W, Kucharz J. Domański P, et al. Among authors: dumnicka p. Biomedicines. 2024 Feb 9;12(2):413. doi: 10.3390/biomedicines12020413. Biomedicines. 2024. PMID: 38398014 Free PMC article.
Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study.
Domański P, Jarosińska J, Kruczyk B, Piętak M, Mydlak A, Demkow T, Kuncman Ł, Darewicz M, Sikora-Kupis B, Dumnicka P, Kucharz J. Domański P, et al. Among authors: dumnicka p. Contemp Oncol (Pozn). 2023;27(3):190-197. doi: 10.5114/wo.2023.133545. Epub 2023 Dec 7. Contemp Oncol (Pozn). 2023. PMID: 38239858 Free PMC article.
First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure.
Sikora-Kupis B, Domański P, Fortuniak W, Kruczyk B, Staneta S, Piętak M, Mydlak A, Demkow T, Dumnicka P, Kucharz J. Sikora-Kupis B, et al. Among authors: dumnicka p. Contemp Oncol (Pozn). 2023;27(4):224-229. doi: 10.5114/wo.2023.134751. Epub 2024 Feb 10. Contemp Oncol (Pozn). 2023. PMID: 38405211 Free PMC article.
92 results